Nindhana Paranthaman
Vice President, Early Clinical Development, Bicara Therapeutics | Oncology Trials, Protocol Design & Biomarker-Driven Prioritization
Nindhana Paranthaman is Vice President, Early Clinical Development at Bicara Therapeutics, where she leads early clinical development in oncology.
A physician by training, she added a business degree after medical school, driven by what she saw of patient access gaps inside health systems. She has described the biopharma sector as where she believed she could have the most impact on patient populations at scale, and her work since has centered on bringing first-in-class therapeutics to multiple markets. Before Bicara she worked in global medical affairs at large pharmaceutical companies.
Her focus areas are protocol design, dosing strategy, and biomarker and pathology-driven prioritization. On Open Door Salon she argued that the AI gains that have genuinely arrived in clinical development are operational, and that the least glamorous work, protocol development and reducing protocol amendments, is where the clearest remaining opportunity sits.
Frequently Asked Questions About Nindhana Paranthaman
Who is Nindhana Paranthaman?
Nindhana Paranthaman is Vice President, Early Clinical Development at Bicara Therapeutics, where she leads early clinical development in oncology. A physician by training, she added a business degree after medical school, driven by what she saw of patient access gaps inside health systems. Before Bicara she worked in global medical affairs at large pharmaceutical companies.
What is Nindhana Paranthaman an expert in?
Nindhana Paranthaman works on protocol design, dosing strategy, and biomarker and pathology-driven prioritization in early-phase oncology trials. Her experience covers bringing first-in-class therapeutics to multiple markets, and the operational side of running clinical studies, including patient recruitment and retention.
How does Nindhana Paranthaman approach protocol development?
Nindhana Paranthaman treats the front end of a trial as the place with the clearest remaining opportunity. She has argued that protocol development, and reducing the protocol amendments that follow, has a direct operational effect on how a study recruits across sites and countries, even though the work is not glamorous.
What organizations is Nindhana Paranthaman associated with?
Nindhana Paranthaman is Vice President, Early Clinical Development at Bicara Therapeutics, a clinical-stage biotechnology company. She previously held roles in global medical affairs at large pharmaceutical companies.
On Open Door Salon
“Nindhana Paranthaman and Paul Agapow on What AI Delivered in Clinical Development”
Nindhana Paranthaman & Paul Agapow · September 23, 2026
Episode page & show notes on Open Door Salon
In this episode
- What AI actually delivered in clinical development, and what never arrived
- Why a trial completed inside a year is marketing
- What a digital twin is, and why it cannot replace a patient
- Where digital twins could genuinely work
- About a third of today’s AI work survives five years
- Protocols, amendments and the unglamorous gold
- Why biology breaks AI: discovered, not invented
- Target herding and what investors should ask
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →